Inventor · disambiguated record
Gregory P. Adams
Also filed as: ADAMS GREGORY P · ADAMS GREGORY PAUL
13 granted patents·2 pending applications·225 citations·filing 2003–2023
91Inventor score
Files withADAMS GREGORY P4ELUCIDA ONCOLOGY INC3MUSCULOSKELETAL TRANSPLANT FOUNDATION2UNIV CALIFORNIA2CALIFORNIA UNIVERSITY1
Top patents by PatentIndex Score
15 records- 0195US8329873B2Bispecific single chain Fv antibody molecules and methods of use thereofADAMS GREGORY P·Filed 2007·Granted Dec 11, 2012·28 cites·17 claims
- 0295US7332580B2Bispecific single chain Fv antibody molecules and methods of use thereofUNIV CALIFORNIA·Filed 2003·Granted Feb 19, 2008·76 cites·9 claims
- 0393US7332585B2Bispecific single chain Fv antibody molecules and methods of use thereofCALIFORNIA UNIVERSITY·Filed 2005·Granted Feb 19, 2008·60 cites·13 claims
- 0491US8580263B2Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereofADAMS GREGORY P·Filed 2007·Granted Nov 12, 2013·20 cites·18 claims
- 0588US11744897B2Folate receptor targeted nanoparticle drug conjugates and uses thereofELUCIDA ONCOLOGY INC·Filed 2022·Granted Sep 5, 2023·2 cites·30 claims
- 0686USD856517SAsymmetric tissue graftMUSCULOSKELETAL TRANSPLANT FOUNDATION·Filed 2016·Granted Aug 13, 2019·30 cites·1 claims
- 0774US11957760B2Folate receptor targeted nanoparticle drug conjugates and uses thereofELUCIDA ONCOLOGY INC·Filed 2023·Granted Apr 16, 2024·0 cites·30 claims
- 0874US8980258B2Bispecific single chain Fv antibody molecules and methods of use therofUNIV CALIFORNIA·Filed 2012·Granted Mar 17, 2015·1 cites·21 claims
- 0974US7781568B2Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancerFOX CHASE CANCER CT·Filed 2006·Granted Aug 24, 2010·2 cites·17 claims
- 1072US8198411B2Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancerADAMS GREGORY P·Filed 2010·Granted Jun 12, 2012·2 cites·10 claims
- 1171US10945831B2Asymmetric tissue graftMUSCULOSKELETAL TRANSPLANT FOUNDATION·Filed 2016·Granted Mar 16, 2021·3 cites·14 claims
- 1270US2023241243A1Carrier particle-drug conjugates, self-immolative linkers, and uses thereofELUCIDA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 1363US9611321B2Rationally-designed anti-mullerian inhibiting substance type II receptor antibodiesADAMS GREGORY P·Filed 2012·Granted Apr 4, 2017·1 cites·14 claims
- 1439US11261225B2Chimera of bone morphogenic protein 2 and the Müllerian-inhibiting substance type II receptor binding region of Müllerian-inhibiting substanceTHE RES INSTITUTE OF FOX CHASE CANCER CENTER·Filed 2018·Granted Mar 1, 2022·0 cites·24 claims
- 1539US2013108547A1Recombinantly Produced Antibodies Targeting ErbB Signaling Molecules and Methods of Use Thereof for the Diagnosis and Treatment of DiseaseDUNBRACK ROLAND·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gregory P. Adams files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →